Veradermics MANE

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Companies in Drug Manufacturers - General nearest Veradermics' size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
MANEVeradermics	$5.8B	n/m	n/a		n/m	n/m	n/m
KNSAKiniksa Pharmaceuticals International	$6B	79.1×	85.3×		7.1×	+59%	9.6%
LGNDLigand Pharmaceuticals	$6.1B	32.3×	37.7×		20.8×	+55%	67.9%
AMRXAmneal Pharmaceuticals	$6.5B	41.6×	51.5×		2.1×	+9%	5.0%
ALKSAlkermes plc.	$7.3B	115×	16.0×		4.4×	+11%	4.0%
INDVIndivior Pharmaceuticals	$4.1B	12.4×	20.1×		3.1×	+13%	26.7%
TGTXTG Therapeutics	$8.3B	19.8×	19.4×		10.4×	+76%	55.2%
ARQTArcutis Biotherapeutics	$3.9B	142×	115×		8.5×	+76%	6.1%
LQDALiquidia	$3.8B	30.7×	53.6×		8.5×	n/m	30.7%
PTGXProtagonist Therapeutics	$9B	134×	58.3×		31.8×	+35%	29.4%
CORTCorcept Therapeutics	$9.3B	204×	28.3×		11.2×	+16%	6.6%
Peer median	$6.3B	60.3×	44.6×		8.5×	+35%	18.1%

Investors we follow who held Veradermics at the end of Jun 30, 2026, from their 13F filings.

• Lee AinslieMaverick Capital0.9% of portfolionew
• Andreas HalvorsenViking Global Investors0.5% of portfoliotrimmed
• Ron BaronBaron Capital0.0% of portfolioadded

Each number over time

• EPS
• Free cash flow
• Shares outstanding

Its groups

• Drug Manufacturers - General
• Healthcare

Industry

Drug Manufacturers - General

Sector

Healthcare